Back to today’s briefing

Story perspectives

Seaport Therapeutics Launches Phase 2b Study for Depression Drug

7/18/2025

40 4

Summary

Story summary

Seaport Therapeutics has launched the phase 2b BUOY-1 study for GlyphAllo (SPT-300), targeting major depressive disorder with or without anxious distress. With around 360 participants set to join, this six-week trial aims to assess GlyphAllo's safety and effectiveness, offering hope to the 280 million people worldwide battling depression.

1 of 1

Story summary

Seaport Therapeutics has launched the phase 2b BUOY-1 study for GlyphAllo (SPT-300), targeting major depressive disorder with or without anxious distress. With around 360 participants set to join, this six-week trial aims to assess GlyphAllo's safety and effectiveness, offering hope to the 280 million people worldwide battling depression.